1 active not recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
Follow Chordoma (Poorly Differentiated or De-differentiated): new trials by email Literature Review of Chordoma (Poorly Differentiated or De-differentiated) trials Research Report on Chordoma (Poorly Differentiated or De-differentiated)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers Nivolumab, Ipilimumab - Malignant Rhabdoid Tumor, Rhabdoid Tumor of the Kidney | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 30 | 2020-08-14 | 2026-10-20 |
Chordoma (1) · Rhabdoid Tumor (1) · Sarcoma (1)
Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Complex and Mixed (1) · Neoplasms, Connective and Soft Tissue (1) · Neoplasms, Germ Cell and Embryonal (1)
Ipilimumab (1) · Nivolumab (1)
Dana-Farber Cancer Institute (1)
United States (1)